Researchers Report on Efficacy of Pfizer's Xalkori in MET-mutated Lung Cancer

Jan 13, 2020

|

NEW YORK – In an expansion cohort of the Phase I PROFILE 1001 trial, 32 percent of advanced non-small cell lung cancer patients with MET exon 14 alterations saw their tumors shrink when treated with crizotinib (Pfizer's Xalkori).

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Breaking News

Mar

11

Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar

23

Featured Webinar

ctDNA MRD Detection and Personalized Oncogenomic Analysis in Colorectal Cancer

This webinar will discuss findings from the study, in which molecular residual disease (MRD) was assessed using circulating tumor DNA (ctDNA) without prior mutational knowledge in oligometastatic colorectal cancer (CRC) patients who had received neoadjuvant chemotherapy. This study also investigated urine as an alternative analyte for ctDNA MRD detection.

Mar

25

Featured Webinar

Virtual Molecular Tumor Board Series: What to Do with a ‘Negative’ Molecular Panel Case

In this session, the fourth in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling identified no clear molecular markers to help guide personalized therapy.

Mar

30

Featured Webinar

Circulating Tumor Cells in Breast Cancer: Understanding a Validated Diagnostic Tool for Precision Medicine

This webinar will provide an overview of the current state of circulating tumor cell (CTC) enumeration for clinical use in metastatic breast cancer.

Menu

Researchers Report on Efficacy of Pfizer's Xalkori in MET-mutated Lung Cancer

To read the full story....

Breaking News

UK's NICE Does Not Recommend Lynparza for BRCA-Mutated Prostate Cancer

Allarity Therapeutics Begins European Study of Ixempra for Biomarker-Selected Breast Cancer Patients

Amgen to Acquire Five Prime Therapeutics for $1.9B

Kronos Bio to Proceed With Phase III Trial of Entospletinib in NPM1-Mutated AML

C2i Genomics Acquires Sequencing Lab QNA Dx

FDA Expands Approval of Pfizer's Lorbrena to First-Line ALK-Positive NSCLC; Approves Roche CDx

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

ctDNA MRD Detection and Personalized Oncogenomic Analysis in Colorectal Cancer

Virtual Molecular Tumor Board Series: What to Do with a ‘Negative’ Molecular Panel Case

Circulating Tumor Cells in Breast Cancer: Understanding a Validated Diagnostic Tool for Precision Medicine

What's Popular?

UK's NICE Does Not Recommend Lynparza for BRCA-Mutated Prostate Cancer

McKesson-led Consortium to Establish Best Practices for Lung Cancer Molecular Testing, Treatment

FDA Expands Approval of Pfizer's Lorbrena to First-Line ALK-Positive NSCLC; Approves Roche CDx

Amgen to Acquire Five Prime Therapeutics for $1.9B

MSK Study Finds Survival Gap Between Clinical Trial, Real-world Patients on Approved Cancer Drugs

Sponsorships